Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT ID: NCT03210740

Last Updated: 2019-04-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-06
• Study Completion Date: 2018-04-24

Brief Summary

To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of Actinic Keratosis (AK) Lesions

Detailed Description

A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK) Lesions

Conditions

Actinic Keratosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

AM001 Cream, 7.5%

A white to off-white Cream free from any foreign particles

Group Type: EXPERIMENTAL

AM001 Cream, 7.5%

Intervention Type: DRUG

Active Cream

Vehicle Cream

A white to off-white Cream free from any foreign particles

Group Type: PLACEBO_COMPARATOR

Vehicle Cream

Intervention Type: DRUG

Placeo

Interventions

AM001 Cream, 7.5%

Active Cream

Intervention Type: DRUG

Vehicle Cream

Placeo

Intervention Type: DRUG

Other Intervention Names

Potassium Dobesilate; Placebo Cream

Eligibility Criteria

Inclusion Criteria

1. Subject must provide written informed consent.

2. Subject must be male or non-pregnant females of any race, and any skin type aged 18 to 80 years both inclusive.

3. Subject has 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions, each at least 4 mm in diameter within a 25cm² contiguous treatment area on the face or the balding scalp.

4. Subject is willing to avoid exposure to sunlight, use of tanning booths, sunlamps, or nonprescription UV (ultra-violate) light sources during the study period.ooths, sunlamps, or nonprescription UV (ultra-violate) light sources during the study period.

5. If female subject of childbearing potential, the subject must have a negative urine pregnancy test at Visit 1/ Screening and must have been using an acceptable form of birth control for at least 2 months prior to Visit 1/ Screening and is willing to continue birth control during the study.

6. Subject must be willing and able to understand and comply with the requirements of the study, apply the assigned investigational product as instructed, return for the required study visits, comply with therapy prohibitions.

7. Subject must be in good health, as confirmed by medical history and physical exam, and free from any clinically significant disease/condition, other than actinic keratosis, that might interfere with the study evaluations.

Exclusion Criteria

1. Subject has very thick and/or hyperkeratotic actinic keratosis AK lesions in the treatment area.

2. Subject has used topical treatment of actinic keratosis in the treatment area with 5-fluorouracil, imiquimod, diclofenac, corticosteroids or retinoids within 1 month prior to Visit 2/Baseline or during the study.

3. Subject has used treatment with PDT (photodynamic therapy) or physical therapies (e. g. cryotherapy, curettage or surgical treatment) in the treatment area within 1 month prior to Visit 2/Baseline or during the study.

4. Subject has used chemical peel, dermabrasion, laser abrasion, PUVA (prosalen plus ultraviolet A) therapy or UVB therapy within 6 months prior to Visit 2/Baseline or during the study.

5. Subject has used immunomodulators or immunosuppressive therapies, interferon, oral corticosteroids, oral retinoids or cytotoxic drugs within 1 month prior to Visit 2/Baseline or during the study.

6. Subject has untreated basal cell carcinoma, squamous cell carcinoma or melanoma in the treatment area.

7. Subject has suntan or tattoos that may interfere with the assessments in the treatment area.

8. Subject has dermatological diseases in the treatment area that may interfere with the assessments, e.g. acute skin inflammation, atopic dermatitis, eczema, rosacea, psoriasis, seborrheic dermatitis, peri-oral dermatitis or hyperpigmentation.

9. Subject who consumes excessive amount of alcohol, abuse or have any condition that in the investigator's opinion would compromise compliance, with this protocol.

10. Subject has history of malignancy not in remission for at least 5 years excluding basal cell carcinoma and nonperiorificial squamous cell carcinoma of the skin.

11. Female subject who is pregnant, nursing or planning a pregnancy within the study participation period

12. Subject has symptoms of a clinically significant illness that may influence the outcome of the study in the 4 weeks prior to Visit 1/Screening.

13. Subject has participated in another clinical trial involving investigational product or device in the 4 weeks prior to Visit 1/Screening.

14. Subject has known allergic reactions to components of the investigational product.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AmDerma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

AmDerma Pharmaceuticals, LLC

High Point, North Carolina, United States

Countries

United States

Other Identifiers

AD-AM001-AK1

Identifier Type: -

Identifier Source: org_study_id